Ga. Presicce et Xz. Yang, PARTHENOGENETIC DEVELOPMENT OF BOVINE OOCYTES MATURED IN-VITRO FOR 24-HR AND ACTIVATED BY ETHANOL AND CYCLOHEXIMIDE, Molecular reproduction and development, 38(4), 1994, pp. 380-385
This research was undertaken to improve development of parthenogenetic
embryos following various combined treatments of ethanol and cyclohex
imide. In Experiment 1 in vitro matured oocytes (IVM, 24 hr) were trea
ted with 7% ethanol for 5 min followed by incubation in 10 mu g/ml cyc
loheximide in Medium 199 for 0 (control), 5, 10, and 20 hr. Developmen
t to 2-8 cells following culture for 3 days was similar among treated
groups (32-41%; P > 0.05), which was higher than that of controls (6%;
P < 0.05). Experiment 2 compared pre-ethanol exposures for 0, 1, 2.5,
and 5 min, followed by 5 hr cycloheximide treatment on activation dev
elopment. One- to 5-min groups resulted in 42-44% cleavage contrasted
to 1-12% for controls (P < 0.05). Experiment 3 examined the effect on
oocyte development of ethanol and different concentrations of cyclohex
imide (0, 1, 5, and 10 mu g/ml). Cleavage to 2-8 cells was similar amo
ng the 5 and 10 mu g/ml cycloheximide groups (36% and 42%, P > 0.05) b
ut lower (P < 0.05) for the 1 mu g/ml group (24%) and the controls (2-
13%). When 5 mu g/ml cycloheximide was used (Experiment 4), pre-exposu
re to ethanol (1, 2.5, and 5 min) resulted in more oocytes cleaved (38
-41%) than in the cycloheximide alone group (0%) or the control (0%, P
< 0.05). Experiment 5 tested blastocyst development of the activated
oocytes with or without cytochalasin B treatment. Oocytes developed to
blastocysts were 0%, 14%, 3%, and 3% (P < 0.05), respectively, for co
ntrol, treatment with ethanol and cycloheximide in the presence, or ab
sence of cytochalasin B, or electrical pulse plus cycloheximide. In co
nclusion, the combined ethanol and cycloheximide treatment supported h
igh rates of parthenogenetic development using 24 hr IVM bovine oocyte
s. Blastocyst rate was significantly higher when cytochalasin B was ad
ded to the combined activation regimen. (C) 1994 Wiley-Liss, Inc.